Онлайн книга «Здоровье без побочных эффектов»
|
2. Moynihan R., Cassels A. Selling Sickness: how the world’s biggest pharmaceutical companies are turning us all into patients. New York: Nation Books; 2005. 3. Weingart S.N., Wilson R.M., Gibberd R.W., et al. Epidemiology of medical error. BMJ. 2000; 320: 774–7. 4. Starfield B. Is US health really the best in the world? JAMA. 2000; 284: 483–5. 5. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279: 1200–5. 6. Ebbesen J., Buajordet I., Erikssen J., et al. Drug-related deaths in a department of internal medicine. Arch Intern Med. 2001; 161: 2317–23. 7. Archibald K., Coleman R., Foster C. Open letter to UK Prime Minister David Cameron and Health Secretary Andrew Lansley on safety of medicines. Lancet. 2011; 377: 1915. 8. Centers for Disease Control and Prevention. Leading Causes of Death. Available online at: www.cdc.gov/nchs/fastats/lcod.htm (accessed 5 February 2013). 9. Lenzer J. Anticoagulants cause the most serious adverse events, finds US analysis. BMJ. 2012; 344: e3989. 10. Centers for Disease Control and Prevention. Tobacco-Related Mortality. Available online at: www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/tobacco_related_mortality/ (accessed 2 February 2013). 11. Iyer S., Naganathan V., McLachlan A.J., et al. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging. 2008; 25: 1021–31. 12. Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008. 13. Rennie D. When evidence isn’t: trials, drug companies and the FDA. J Law Policy. 2007 July: 991–1012. 14. Kassirer J.P. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005. 15. Smith R. The Trouble with Medical Journals. London: Royal Society of Medicine; 2006. 16. Brownlee S. Overtreated: why too much medicine is making us sicker and poorer. New York: Bloomsbury; 2007. 17. World Health Organization. World Health Report 2003 – shaping the future. 2003. Available online at: www.who.int/whr/2003/annex_4_en.xls (accessed 20 December 2012). 18. Reinhardt U.E., Hussey P.S., Anderson G.F. U.S. health care spending in an international context. Health Aff (Millwood). 2004; 23: 10–25. 19. Roehr B. Health care in US ranks lowest among developed countries, Commonwealth Fund study shows. BMJ. 2008; 337: a889. 20. Starfield B., Shi L., Grover A., et al. The effects of specialist supply on populations’ health: assessing the evidence. Health Aff (Millwood). 2001 March 15. DOI: 10.1377/hlthaff.w5.97. 21. World Health Organization. The World Medicines Situation. Available online at: http://apps.who.int/medicinedocs/en/d/Js6160e/6.html#Js6160e6. (accessed 6 February 2013). 22. Wealth but not health in the USA. Lancet. 2013; 381: 177. 23. Nolte E., McKee C.M. Measuring the health of nations: updating an earlier analysis. Health Aff (Millwood). 2008; 27: 58–71. 24. Avendano M., Glymour M.M., Banks J., et al. Health disadvantage in US adults aged 50 to 74 years: a comparison of the health of rich and poor Americans with that of Europeans. Am J Public Health. 2009; 99: 540–8. 25. Jachuck S.J., Brierley H., Jachuck S., et al. The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract. 1982; 32: 103–5. 26. Krogsbøll L.T., Jørgensen K.J., Grønhøj Larsen C., et al. General health checks for reducing morbidity and mortality from disease. Cochrane Database Syst Rev. 2012; 10: CD009009. 27. Johnston M.E., Gibson E.S., Terry C.W., et al. Effects of labelling on income, work and social function among hypertensive employees. J Chronic Dis. 1984; 37: 417–23. 28. Butt D.A., Mamdani M., Austin P.C., et al. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012; 172: 1739–44. 29. Abramson J. Overdo$ed America. New York: HarperCollins; 2004. 30. Oliver M. Let’s not turn elderly people into patients. BMJ. 2009; 338: b873. 31. Cacciotti J., Clinton P. Pharm Exec 50: growth from the bottom up. Pharmaceutical Executive. 2012 May 1. Available online at: www.pharmexec.com/pharmexec/Noteworthy/Pharm-Exec-50-Growth-from-the-Bottom-Up/ArticleStandard/Article/detail/773562 (accessed 17 July 2013). 32. Berwick D.M., Hackbarth, A. Eliminating waste in US health care. JAMA. 2012; 307: 1513–16. 33. Liberati A., Magrini N. Information from drug companies and opinion leaders. BMJ. 2003; 326: 1156–7. 34. Tanne J.H. US healthcare executives hit pay jackpot. BMJ. 2011; 343: d8330. 35. Whelton R.S. Effects of Excessive CEO Pay on U.S. Society. Available online at: www.svsu.edu/emplibrary/Whelton%20article.pdf (accessed 6 November 2007). 36. Schafer A. Biomedical confl icts of interest: a defence of the sequestration thesis – learning from the cases of Nancy Olivieri and David Healy. J Med Ethics. 2004; 30: 8–24. 37. Relman A. A Second Opinion: rescuing America’s health care. New York: Public Affairs; 2007. 38. Krimsky S. Science in the Private Interest: has the lure of profits corrupted biomedical research? Lanham: Rowman & Littlefield; 2003. 39. Braithwaite J. Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul; 1984. 40. Goozner M. The $800 Million Pill: the truth behind the cost of new drugs. Berkeley: University of California Press; 2005. 41. Abraham J. Science, Politics and the Pharmaceutical Industry. London: UCL Press; 1995. 42. Day M. MRC says it will invent, develop, and market its own drugs. BMJ. 2007; 334: 1025. 43. Bloemen S., Hammerstein D. Time for the EU to lead on innovation. Health Action International Europe and Trans Atlantic Consumer Dialogue. 2012 April. 44. Bassand J.-P., Martin J., Rydén L., et al. The need for resources for clinical research: The European Society of Cardiology calls for European, international collaboration. Lancet. 2002; 360: 1866–9. 45. Gøtzsche P.C., Hansen M., Stoltenberg M., et al. Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol. 1996; 25: 194–9. 46. Relman A.S., Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41. |